secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001171843-25-007879
Event type: litigation
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus updates LNP litigation; Moderna trial March 2026, Pfizer/BioNTech awaits scheduling
--------------------------------------------------------------------------------

- Global COVID-19 vaccine sales since launch total ~$145BN between Moderna and Pfizer/BioNTech.
- US Moderna jury trial set for March 9, 2026 in Delaware; summary judgment/Daubert rulings expected before trial.
- Ex-US Moderna litigation initial hearings expected in 2026 in UPC, Japan, Switzerland, Canada.
- Pfizer/BioNTech litigation: Markman ruling in Sep 2025 viewed favorably; awaiting trial scheduling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325007879/0001171843-25-007879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325007879/f8k_121025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer